About Us
IMUNAR’s scientists discovered that some human tumors grow when a lack of production of three cytokines by the fighting immune cells present inside the tumor occurs. These three cytokines (immune system hormones) are necessary to induce a tumor fighting type-1 inflammatory response (T1-IR) in the tumor. IMUNAR’s cofounder findings were confirmed by several other scientists worldwide. Subsequent studies showed that patients experiencing spontaneous tumor regression or long-term tumor free survival had an active type-1 inflammation present inside their shrinking tumors. Presence of active type-1 inflammation has been associated with tumor elimination in 6 different tumor types in humans up to now. Those include tumors from the breast, bladder, and colon, lung, kidney and skin.
IMUNAR has developed a cancer biotreatment T1-IRTM consisting to provide the missing cytokines directly in the tumor to activate the cancer-fighting immune cells to eliminate the tumor mass.
The working principle is that delivering a composition of these cytokines directly inside the tumor to immune cells fighting the cancer cells is inducing tumor regression and elimination by the patient’s immune system. The treatment modality is called protein therapeutic and is already in use to treat diabetes, anemia and others. Patients injected with protein therapeutics such as insulin or erythropoietin overcome their diabetes or anemia. IMUNAR’s protein therapeutic composition induces a type-1 inflammation inside the tumor to help patients overcome their cancer.
There are eight million Americans currently battling cancer. And there is 2.4 million new patients seeking cancer treatment annually in the U.S.A. Forty-three percent of these patients will die within 5 years. There is a crucial need for better therapy. IMUNAR’s T1-IRTM has been granted patents in the U.S.A., Europe, Mexico, Singapore and soon in Canada. We are dedicated to bring this novel cancer therapy to cancer patients as rapidly as possible.